Scenarios that move TAK
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Scenarios that move TAK: 7 analyses, 1 positive, 6 negative.
- · Mirum's Livmarli meets Phase III goal in ultra-rare liver diseases — ▲ · impact +26 · confidence medium · horizon quarters
- · argenx meets primary endpoint in Phase II celiac disease study — ▼ · impact -40 · confidence medium · horizon quarters
- · Spyre Therapeutics prices $350 million public stock offering — ▼ · impact -18 · confidence low · horizon quarters
- · Ionis reports positive late-stage results for two partnered drugs — ▼ · impact -30 · confidence low · horizon quarters
- · Oruka Therapeutics reports positive week 28 ORKA-001 trial data — ▼ · impact -20 · confidence low · horizon quarters
- · Ascendis announces planned $400 million share repurchase program — ▼ · impact -14 · confidence low · horizon quarters
- · Japan spends $80B in foreign reserves to save yen — ▼ · impact -42 · confidence medium · horizon quarters